Levels and patterns of prenatal alcohol exposure associated with increased risk of a clinically meaningful adverse effect on cognitive function
- PMID: 41387301
- DOI: 10.1111/acer.70208
Levels and patterns of prenatal alcohol exposure associated with increased risk of a clinically meaningful adverse effect on cognitive function
Abstract
Background: Recent interest in the screening and diagnosis of fetal alcohol spectrum disorders (FASD) by the American Psychiatric Association and the American Association of Pediatrics has highlighted the lack of empirical evidence regarding the levels and patterns of prenatal alcohol exposure (PAE) associated with clinically significant adverse effects on cognitive and behavioral function. We used benchmark dose analysis to address this issue.
Methods: Benchmark dose analyses were performed on composite cognitive function scores derived from data obtained at school age, adolescence, and early adulthood from 2227 participants from six prospective, longitudinal cohorts, whose mothers were interviewed about their alcohol and drug use during pregnancy or shortly thereafter. We compared single-predictor models based on average alcohol consumed per day during pregnancy with a two-predictor, semiparametric model based on (1) average alcohol dose per drinking occasion and (2) drinking frequency.
Results: Our two-predictor model showed that at lower levels of drinking frequency, a relatively high dose/occasion is required for an increased risk of poor intellectual function, whereas at higher levels of drinking frequency, a lower dose/occasion is sufficient to increase that risk. In addition, lower doses/occasion were associated with clinically meaningful adverse effects in participants born to older than to younger mothers. The single-predictor models proved less adequate because the dose/occasion for a substantial proportion of participants exposed at the benchmark doses generated by those models was too low to increase the risk of clinically significant effects.
Conclusions: Given that the cognitive and behavioral deficits seen in FASD resemble those also seen in a range of other disorders, whether the patient's PAE is sufficient to increase the risk of clinically meaningful impairment is a critical element in an FASD diagnosis. Accurate diagnosis is needed to determine which patients warrant interventions that have been shown to be effective in remediating PAE-related neurobehavioral impairment.
Keywords: benchmark dose analysis; clinically significant effects; cognitive function; diagnosis; fetal alcohol spectrum disorders; fetal alcohol syndrome; prenatal alcohol exposure.
© 2025 Research Society on Alcohol.
References
REFERENCES
-
- Abel, E.L. & Dintcheff, B.A. (1984) Factors affecting the outcome of maternal alcohol exposure: I. Parity. Neurobehavioral Toxicology and Teratology, 6, 373–377.
-
- Akkaya‐Hocagil, T., Ryan, L.M., Cook, R.J., Dang, K.D., Carter, R.C., Richardson, G.A. et al. (2024) Benchmark dose profiles for bivariate exposures. Risk Analysis, 44, 2415–2428.
-
- American Academy of Pediatrics. (2012) AAP endorses statement on alcohol‐related developmental disabilities. AAP News, 33, 18.
-
- American Psychiatric Association. (2013) Diagnostic and statistical manual of mental disorders, 5th edition. Arlington, VA: APA.
-
- American Psychiatric Association. (2022) Diagnostic and statistical manual of mental disorders, 5th edition, text revision. Washington, DC: APA.
MeSH terms
Substances
Grants and funding
- P50 AA07606/AA/NIAAA NIH HHS/United States
- R01 AA025905/AA/NIAAA NIH HHS/United States
- R01 AA06390/AA/NIAAA NIH HHS/United States
- R01 AA06666/AA/NIAAA NIH HHS/United States
- R01 AA06966/AA/NIAAA NIH HHS/United States
- R01 AA08105/AA/NIAAA NIH HHS/United States
- R01 AA09524/AA/NIAAA NIH HHS/United States
- R01 AA10108/AA/NIAAA NIH HHS/United States
- R01 AA14215/AA/NIAAA NIH HHS/United States
- R01 AA18116/AA/NIAAA NIH HHS/United States
- R01 AA13272/AA/NIAAA NIH HHS/United States
- R01 AA01455/AA/NIAAA NIH HHS/United States
- Lycaki-Young Fund from the State of Michigan
- CE140100049/Australian Research Council Centre of Excellence for Mathematical and Statistical Frontiers
- RGPIN 155849/Natural Sciences and Engineering Research Council of Canada
- RGPIN 04207/Natural Sciences and Engineering Research Council of Canada
- R21 DA021034/DA/NIDA NIH HHS/United States
- HD036890/Eunice Kennedy Shriver National Institute on Child Health and Human Development
- R01 DA00090/NIDA/NIH
- R01 DA03209/NIDA/NIH
- R01 DA03874/NIDA/NIH
- R01 DA17786/NIDA/NIH
- R01 DA05460/NIDA/NIH
- R01 DA06839/NIDA/NIH
- R01 DA08916/NIDA/NIH
- R01 DA12401/NIDA/NIH
- R01 DA0737362/NIDA/NIH
- P50 AA07606/AA/NIAAA NIH HHS/United States
- R01 AA025905/AA/NIAAA NIH HHS/United States
- R01 AA06390/AA/NIAAA NIH HHS/United States
- R01 AA06666/AA/NIAAA NIH HHS/United States
- R01 AA06966/AA/NIAAA NIH HHS/United States
- R01 AA08105/AA/NIAAA NIH HHS/United States
- R01 AA09524/AA/NIAAA NIH HHS/United States
- R01 AA10108/AA/NIAAA NIH HHS/United States
- R01 AA14215/AA/NIAAA NIH HHS/United States
- R01 AA18116/AA/NIAAA NIH HHS/United States
- R01 AA13272/AA/NIAAA NIH HHS/United States
- R01 AA01455/AA/NIAAA NIH HHS/United States
- R21 DA021034/DA/NIDA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
